MLTX FY2025 SEC EDGAR DEF 14A #147 of 168 in industry

MoonLake Immunotherapeutics CEO pay ratio

The CEO earned $1.9M in FY2025 against median worker pay of $237,155 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
E9
Filing date
2026-04-21
Industry
Chemicals & Pharmaceuticals
Industry rank
#147/168

Data updated August 2026

Subscribe to MoonLake Immunotherapeutics CEO pay filing updates (RSS)

CEO-to-worker pay ratio
8:1
Below Average (Scale: 0–1000:1)
CEO pay
$1.9M
Median worker
$237,155

Answer first

MoonLake Immunotherapeutics's FY2025 CEO total of $1.9M ranks #1161 of 1,423 complete filings; its 8:1 pay ratio ranks #1309. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $237,155. Industry placement uses the FY2025 SIC-28 peer cohort (# 147 of 168, 13th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1161
$1.9M of 1,423 FY2025
Ratio rank
#1309
8:1 of 1,423
Industry pct
13th
among the lower quartile of industry peers by pay ratio

How MoonLake Immunotherapeutics ranks nationally

MoonLake Immunotherapeutics CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$1,897,240 18th percentile higher than 18% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

MoonLake Immunotherapeutics vs. Chemicals & Pharmaceuticals peers

CEO total pay ($1.9M) against pay ratio (8:1) for MoonLake Immunotherapeutics (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both727977.32606242.44484507.56362772.68241037.86.3:115.7:125.0:134.4:143.7:1CEO total payPay ratio (CEO : median worker)MoonLake Immunotherapeutics, CEO total pay: 1897240 · Pay ratio (CEO : median worker): 8:1MoonLake ImmunotherapeuticsCollegium Pharmaceutical, Inc, CEO total pay: 1715846 · Pay ratio (CEO : median worker): 8:1Collegium Pharmaceutical, IncOmeros Corp, CEO total pay: 1533248 · Pay ratio (CEO : median worker): 8:1Omeros CorpDenali Therapeutics Inc., CEO total pay: 2966856 · Pay ratio (CEO : median worker): 8:1Denali Therapeutics Inc.American Vanguard Corp, CEO total pay: 1069480 · Pay ratio (CEO : median worker): 8:1American Vanguard Corp
MoonLake Immunotherapeutics vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in MoonLake Immunotherapeutics's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · MoonLake Immunotherapeutics

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
8:1
FY2025
vs prior FY
-1:1
from FY2024 9:1
CEO $ YoY
+63%
$1.9M latest
Filings shown
2
FY2024–2025
MoonLake Immunotherapeutics CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $1.2M - $128,943 9:1 -
2025 $1.9M +63% $237,155 8:1 -1:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1821586, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
8:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$1.9M
Companies in Industry
168
vs. Industry Median
Below
#147 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

MoonLake Immunotherapeutics: near-parity Item 402(u) ratio

MoonLake Immunotherapeutics's FY2025 ratio 8:1 ranks #147 of 168 Chemicals & Pharmaceuticals filers (13th percentile). the CEO earned 8× the median employee ($237,155) in FY2025.

At $237,155 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.

CEO Total Pay

$1.9M

FY2025 Summary Compensation, below median

Pay Ratio

8:1

Below typical

MoonLake Immunotherapeutics in the lower Chemicals & Pharmaceuticals third

MoonLake Immunotherapeutics's FY2025 ratio 8:1 ranks #147 of 168 Chemicals & Pharmaceuticals filers (13th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; MoonLake Immunotherapeutics's $1.9M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1161 and ratio rank #1309 split - treat 8:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$1.9M
Median Employee Pay
$237,155
Pay Ratio
8:1
Filing Date
2026-04-21

Company Info

Ticker
MLTX
CIK
1821586
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
E9
View SEC filings →
SEC EDGAR DEF 14A for CIK 1821586, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. MoonLake Immunotherapeutics's FY2025 ratio 8:1 ranks #147 of 168 Chemicals & Pharmaceuticals filers (13th percentile).

Read with MoonLake Immunotherapeutics

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.

Middlesex Water Co · LIGHT

ABS(ceo_total_comp) peer at $1.9M (Δ $9K heavier vs MoonLake Immunotherapeutics); MID · LOW-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Citi Trends Inc · LIGHT

ABS(ceo_total_comp) peer at $1.9M (Δ $15K heavier vs MoonLake Immunotherapeutics); MID · LOW-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Clarus Corp · LIGHT

ABS(ceo_total_comp) peer at $1.9M (Δ $33K lighter vs MoonLake Immunotherapeutics); MODEST · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
GigaCloud Technology Inc · LIGHT

ABS(ceo_total_comp) peer at $1.9M (Δ $36K heavier vs MoonLake Immunotherapeutics); MODEST · LOW-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Collegium Pharmaceutical, Inc (SIC 28 pole)

Collegium Pharmaceutical, Inc stamps FLOOR · LIGHT nearest in-SIC by ABS(pay_ratio) to MoonLake Immunotherapeutics's FLOOR filing.
National dual ranks · #1161/#1309

MoonLake Immunotherapeutics's FY2025 package sits #1161 by CEO dollars and #1309 by ratio under LIGHT · FLOOR.
Ratio primer · FLOOR

MoonLake Immunotherapeutics's FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for MoonLake Immunotherapeutics (CIK 1821586), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.